Publications by authors named "Yu Momose"

Claim this Profile
S
Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.
Kentaro Rikimaru, Takeshi Wakabayashi, Hidenori Abe, Taisuke Tawaraishi, Hiroshi Imoto, Yu Momose

Bioorg Med Chem· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
Satoshi Mikami, Shuji Kitamura, Nobuyuki Negoro, Shinobu Sasaki, Masami Suzuki, Yu Momose

J Med Chem· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
Nobuyuki Negoro, Shinobu Sasaki, Satoshi Mikami, Masahiro Ito, Yoshiyuki Tsujihata, Yu Momose

J Med Chem· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.
Nobuyuki Negoro, Shinobu Sasaki, Masahiro Ito, Shuji Kitamura, Yoshiyuki Tsujihata, Yu Momose

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
Kentaro Rikimaru, Takeshi Wakabayashi, Hidenori Abe, Hiroshi Imoto, Tsuyoshi Maekawa, Yu Momose

Bioorg Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Yoshiyuki Tsujihata, Ryo Ito, Masami Suzuki, Ayako Harada, Nobuyuki Negoro, Yu Momose

J Pharmacol Exp Ther· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Shinobu Sasaki, Shuji Kitamura, Nobuyuki Negoro, Masami Suzuki, Yoshiyuki Tsujihata, Yu Momose

J Med Chem· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
Nobuyuki Negoro, Shinobu Sasaki, Satoshi Mikami, Masahiro Ito, Masami Suzuki, Yu Momose

ACS Med Chem Lett· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Nobuo Cho, Yu Momose

Curr Top Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes.
Junichi Sakamoto, Hiroyuki Kimura, Shinji Moriyama, Hiroshi Imoto, Yu Momose

Eur J Pharmacol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies on non-thiazolidinedione antidiabetic agents. 3. Preparation and biological activity of the metabolites of TAK-559.
Hiroshi Imoto, Mitsuharu Matsumoto, Hiroyuki Odaka, Junichi Sakamoto, Hiroyuki Kimura, Yu Momose

Chem Pharm Bull (Tokyo)· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological activity of novel 5-(omega-aryloxyalkyl)oxazole derivatives as brain-derived neurotrophic factor inducers.
Tsuyoshi Maekawa, Nozomu Sakai, Hiroyuki Tawada, Katsuhito Murase, Masatoshi Hazama, Yu Momose

Chem Pharm Bull (Tokyo)· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents.
Hiroshi Imoto, Yasuo Sugiyama, Hiroyuki Kimura, Yu Momose

Chem Pharm Bull (Tokyo)· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives.
Hiroshi Imoto, Eikoh Imamiya, Yu Momose, Yasuo Sugiyama, Hiroyuki Kimura

Chem Pharm Bull (Tokyo)· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities.
Yu Momose, Tsuyoshi Maekawa, Tohru Yamano, Mitsuru Kawada, Hiroyuki Odaka

J Med Chem· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents.
Yu Momose, Tsuyoshi Maekawa, Hiroyuki Odaka, Hitoshi Ikeda, Takashi Sohda

Chem Pharm Bull (Tokyo)· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis